Plus Therapeutics (PSTV) announced the FDA has conditionally accepted the company's new proprietary name, REYOBIQ, for its lead therapeutic candidate. The company noted that REYOBIQ or rhenium Re186 obisbemeda continues to be under clinical investigation for Leptomeningeal Metastases and Recurrent Glioblastoma.
"Branding is an important part of preparing for commercialization, and the establishment of the REYOBIQ brand will enable investigators, investors, and potential patients to connect with our rhenium-based radiotherapeutic beyond its chemical identity," said Russ Havranek, Plus Therapeutics VP of Corporate Strategy and New Product Planning.
Shares of Plus Therapeutics are up 20% in pre-market trade on Thursday.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
April 10, 2026 16:21 ET Inflation data from the U.S. was the main data event this week as the conflict in the Middle East continue. The minutes of the latest Fed policy session and the survey data on the services sector also made headlines. In Europe, manufacturing orders data from Germany was in focus. Price data from China drew attention in Asia.